GTSIF has possibly developed strong potential support as it now trades above 3 key lines in its:
- 50-Day Simple Moving Average (SMA),
- 200-Day Simple Moving Average, and its
- 13-Day Exponential Moving Average (EMA).
When a valuation falls towards these lines after trading above them, it may bounce back towards previous highs as people can view them as lines of strong potential support.
The more potential support builds up, the more possibility for a continued vertical move up the charts.
Additionally, as of 11:00AM EST Wednesday, GTSIF was trading above its 5-Day EMA and its 13-Day EMA.
On top of that, its 5-Day EMA is trading above its 13-Day EMA which signals a profile that has been trending in the right direction in the short term and could be gaining momentum.
-----
Your No. 3 GTSIF Potential Catalyst - New Company Name / Management Changes
Lobe Sciences Commences Trading Under New Name and Announces Rebranding and Corporate Update
Lobe Sciences unveils new corporate name and logo as part of an extensive rebranding initiative, reflective of the Company's focus on PSYCH medicines
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that today it will commence trading on the Canadian Securities Exchange (the "CSE") under its new name and trading symbol. In connection with the name change, the Company has new CUSIP and ISIN numbers - 53946V107 and CA53946V1076 respectively.
The Company is pleased to announce this milestone along with the launch of its rebranding and marketing campaign that encompasses brand awareness and messaging. As part of the rebranding initiative, the Company has launched a new company website at www.lobesciences.com. While the corporate name is changing, the Company's commitment to being a leader in developing effective therapeutics and devices using PSYCH and other naturally occurring compounds remains as strong as ever.
The Company believes the rebranding better reflects its long-standing business growth initiatives as well as the Company's overall vision. The Company's rebranding strategy retains the core values surrounding its focus on transformational medicine through the use of PSYCH compounds, with a particular focus on wellness, brain and mental health.
Since its inception, Lobe's focus has been to grow its intellectual property portfolio and capitalize on M&A opp's. In 2020, the Company made significant strides and successfully executed on several key growth initiatives to position the Company as a leading PSYCH medicine company.
Read the full article here.
Lobe Sciences Announces Management Changes and New Director
Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2021) - Lobe Sciences Ltd (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company, effective January 15, 2021. Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date.
Philip Young is an accomplished CEO and innovative professional with 25 years of expertise in senior executive management and board roles, with significant mergers and acquisitions and equity financing experience. He has a proven track record in the biotech, medtech and pharmaceutical industries with expertise in dealing with FDA/regulatory frameworks as well as new device and therapeutics development. From 2015 until 2019, Mr. Young was the Founder, Chairman, and CEO of Exactus Inc. ("Exactus"), an OTCQB listed company he successfully transitioned from a medical technology company to a farming focused hemp-derived CBD company.
Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc.), a global biopharmaceutical company. He was also previously the President, CEO and a director of Osteologix Inc., where he was responsible for directing and managing all facets of the global pharmaceutical development company. He is the former Chief Business Officer and Executive Vice President of Insmed Inc., where he directed all financing, corporate and commercial communications activities. Prior thereto, he was the Vice President and General Manager of Neurex Corp., where he was involved with the negotiations for its $700Mn acquisition by Elan Corporation. Mr. Young holds a Bachelor's of Science from James Madison University.
Jonathan Gilbert, Executive Chairman of Lobe, states, "We are very pleased to have Philip join our Lobe executive team. His addition is the latest in our strategy to strengthen our overall team, including recent additions to our industry renowned research and development partner, our board of directors and strategic advisors. Phil brings a wealth of experience in building companies, developing therapeutics and creating shareholder value, which is expected to support our current focus on advancing Lobe's proprietary nasal device, furthering our pre-clinical study with the University of Miami and growing the Company through M&A. He has a demonstrated track record of senior leadership skills, capital markets acumen and FDA and regulatory experience. We will leverage these attributes as we progress with our nasal mist device engineering and overall therapeutics development initiatives involving PSYCH medicine. We are excited by his commitment to achieve the Company's key strategic priorities."
Philip Young states, "I look forward to working closely with Lobe's board and executive team to grow the Company. I see great potential in the Company in this exciting and evolving industry where I can utilize both my therapeutics development/regulatory expertise and M&A experience to add value. We plan on continuing to build on Lobe's progress made to date, in particular on the nasal device engineering and pre-clinical study with the University of Miami, as well as actively pursuing other M&A growth objectives."
Read the full article here.
-----
Your No. 4 GTSIF Potential Catalyst - Nasal Mist Device News
Lobe Sciences Commences Engineering of Nasal Mist Device
Vancouver, British Columbia--(Newsfile Corp. - December 3, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.
This is a major milestone towards the ultimate goal for development of effective delivery methods and commercialization. The Company holds several provisional patent applications including for a nasal mist device entitled "Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder." This device includes a nasal delivery system for administration of pharmaceutical agents such as a psi*lo*cybin-derived agent and/or N-acetylcysteine ("NAC") at preselected dosages and times. The device design allows for the precise control and delivery of medicines through the nasal cavity for faster and more efficient uptake of PSYCH's and other medicines that target the brain.
Tom Baird, CEO of Lobe, states, "The development and advancement of this innovative device will put us at the forefront of delivering effective therapeutics to millions of people who suffer from mild traumatic brain injury, post-traumatic stress disorder and other mental health issues. Development of this device will reimagine the future for PTSD sufferers and radically change the limited treatment options for people who suffer from mTBI and PTSD. We are excited with the progress being made as we pursue our research initiatives including the recent launch of preclinical studies with the University of Miami's Miller School of Medicine."
Paul Seiter, CEO of VisionWorks, said, "This is a great opp. for LOBE and VisionWorks to develop a device that could dramatically improve the delivery of drugs for brain related therapies. We are excited to work with the Lobe team to bring this device to the market."
Read the full article here.
-----
Your No. 5 GTSIF Potential Catalyst - Sale Announcement
Lobe Sciences Announces CAD$23Mn Sale of Cowlitz Can-na-bis Option to Ionic Brands Corp.
Signed LOI for CAD$23Mn sale to Ionic provides shareholder value
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands Corp. ("Ionic") for the proposed sale to Ionic of certain assets held by Lobe related to Cowlitz County Can-na-bis Cultivation Inc. ("Cowlitz") (the "Transaction"). Cowlitz is one of the top five licensed can-na-bis producers/processors located in Washington State.
The assets being sold to Ionic may include, but are not limited to, the assignment of all property leases relating exclusively to Cowlitz's business, the assignment of Lobe's option agreement to acquire all of the outstanding shares of Cowlitz, and the assignment of other contracts and rights related exclusively to Cowlitz including service contracts and equipment leases (the "Assets").
[...]
John Gorst, CEO of Ionic said, "We are excited about this opportunity to expand our presence in Washington State. Cowlitz has tremendous brand presence and following in Washington State, which we feel is a natural fit, complementing our existing operations. The combination will make us one of the largest premier can-na-bis companies in the Pacific Northwest markets. The acquisition of the Cowlitz Assets will represent a complimentary synergistic acquisition that achieves our goal of operational expansion and growth of our product portfolio."
"The proposed transaction with Ionic is accretive to both parties, successfully meets our M&A initiatives and keeps Lobe active in the can-na-bis and overall transformation PSYCH medicine space," states Tom Baird, CEO of Lobe. "The Transaction provides Lobe with significant ownership and board presence in Ionic. With its already significant operations in Washington State and Oregon, we feel Ionic's proposed product expansion initiatives together with the addition of the Cowlitz Assets can lead to aggressive growth."
Read the full article here.
-----
Report Recap: Top 5 Potential Catalysts For GTSIF
No. 1 - Bullish Technical Indicators
No. 2 - Recent Chart Growth / Trading Above Support Levels
No. 3 - New Company Name / Management Changes
No. 4 - Nasal Mist Device News
No. 5 - Cowlitz Sale Announcement
-----
Coverage is officially initiated on GTSIF. When you have a moment, do this:
